Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impaired FADD/BID signaling mediates cross-resistance to immunotherapy in Multiple Myeloma.
Munawar U, Zhou X, Prommersberger S, Nerreter S, Vogt C, Steinhardt MJ, Truger M, Mersi J, Teufel E, Han S, Haertle L, Banholzer N, Eiring P, Danhof S, Navarro-Aguadero MA, Fernandez-Martin A, Ortiz-Ruiz A, Barrio S, Gallardo M, Valeri A, Castellano E, Raab P, Rudert M, Haferlach C, Sauer M, Hudecek M, Martinez-Lopez J, Waldschmidt J, Einsele H, Rasche L, Kortüm KM. Munawar U, et al. Among authors: kortum km. Commun Biol. 2023 Dec 21;6(1):1299. doi: 10.1038/s42003-023-05683-4. Commun Biol. 2023. PMID: 38129580 Free PMC article.
[Multiple myeloma].
Kortüm KM, Engelhardt M, Rasche L, Knop S, Einsele H. Kortüm KM, et al. Internist (Berl). 2013 Aug;54(8):963-77. doi: 10.1007/s00108-013-3336-2. Internist (Berl). 2013. PMID: 23860514 German.
Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease.
Kortüm KM, Langer C, Monge J, Bruins L, Egan JB, Zhu YX, Shi CX, Jedlowski P, Schmidt J, Ojha J, Bullinger L, Liebisch P, Kull M, Champion MD, Van Wier S, Ahmann G, Rasche L, Knop S, Fonseca R, Einsele H, Stewart AK, Braggio E. Kortüm KM, et al. Br J Haematol. 2015 Feb;168(4):507-10. doi: 10.1111/bjh.13171. Epub 2014 Oct 10. Br J Haematol. 2015. PMID: 25302557 Free PMC article.
Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.
Kortüm KM, Mai EK, Hanafiah NH, Shi CX, Zhu YX, Bruins L, Barrio S, Jedlowski P, Merz M, Xu J, Stewart RA, Andrulis M, Jauch A, Hillengass J, Goldschmidt H, Bergsagel PL, Braggio E, Stewart AK, Raab MS. Kortüm KM, et al. Blood. 2016 Sep 1;128(9):1226-33. doi: 10.1182/blood-2016-02-698092. Epub 2016 Jul 25. Blood. 2016. PMID: 27458004 Free PMC article. Clinical Trial.
CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma.
Lapa C, Herrmann K, Schirbel A, Hänscheid H, Lückerath K, Schottelius M, Kircher M, Werner RA, Schreder M, Samnick S, Kropf S, Knop S, Buck AK, Einsele H, Wester HJ, Kortüm KM. Lapa C, et al. Among authors: kortum km. Theranostics. 2017 Apr 8;7(6):1589-1597. doi: 10.7150/thno.19050. eCollection 2017. Theranostics. 2017. PMID: 28529638 Free PMC article.
11C-Methionine-PET in Multiple Myeloma: A Combined Study from Two Different Institutions.
Lapa C, Garcia-Velloso MJ, Lückerath K, Samnick S, Schreder M, Otero PR, Schmid JS, Herrmann K, Knop S, Buck AK, Einsele H, San-Miguel J, Kortüm KM. Lapa C, et al. Among authors: kortum km. Theranostics. 2017 Jul 23;7(11):2956-2964. doi: 10.7150/thno.20491. eCollection 2017. Theranostics. 2017. PMID: 28824728 Free PMC article.
First targeted therapy in multiple myeloma.
Kortüm KM, Einsele H. Kortüm KM, et al. Blood. 2017 Nov 30;130(22):2359-2360. doi: 10.1182/blood-2017-09-805341. Blood. 2017. PMID: 29191974 Free article. No abstract available.
86 results